• Vk
  • LinkedIn
  • Youtube
X7 Research
  • News
  • Registration strategy and Сonsulting
    • Budgeting
    • Registration strategy development
    • Study feasibility
    • Vendor selection
    • Data search and analysis
  • Clinical trials
    • Outsourcing CRAs in Russia and the EAEU
    • Development of medical documentation and biostatistics
    • Monitoring
    • Data-management
    • Patient home visits
    • Bioequivalence study
    • Therapeutic equivalence studies
    • Clinical trials of medical devices
  • Registration
    • Audit of the registration dossier
    • Bringing the registration dossier in compliance with the requirements of the EAEU
    • Conversion of registration dossier into XML format
    • PIL readability user testing
    • Translation of the Registration dossier
    • Turnkey registration
  • Post-authorization clinical studies
    • Phase IV studies
    • Non-interventional studies
    • Investigator-initiated studies
    • Post-authorisation safety study
    • Marketing research
  • Pharmacovigilance
    • QPPV in the EAEU
    • Safety monitoring of medical devices
    • Building a pharmacovigilance system
    • Safety in clinical trials
    • Pharmacovigilance audit
    • Pharmacovigilance contact person
  • Therapeutic expertise
    • Clinical trials in Oncology in the EAEU
  • Contact
  • EnglishEnglish
  • Menu

When there is no choice – EMA and FDA allow early access to market for indispensable medications

12.02.2017/in News /by ValeriiaKirienko

Current regulations in drug development field assume complicated and lengthy multistage process, typically taking years if not decades. Often there are no effective treatment for orphan (rare) diseases, and many patients suffering from such conditions simply can’t last long enough to get effective treatment, especially if their lives depend on the drug under development. There are approximately 60 million people suffering from orphan diseases in the EU and the US, hence the total burden of orphan diseases is huge. Similarly, the approval process is suboptimal if a new drug is being developed for the treatment of serious diseases or for use in emergency situations. EMA grants conditional marketing authorization for such medications since 2006. In other words, the agency gives marketing authorization before all the required data is submitted by the manufacturer. Recently

EMA published a report on the 10-year experience of practicing such approach. At the beginning, this innovation seemed risky: 30 medicines received conditional marketing authorization since 2006 and for half of them phase III trials were not completed by the time of submission. It took an average of 4 years to collect and summarize the additional data needed and to convert a conditional marketing authorization into a full marketing authorization. Yet, no drug has been withdrawn from the market because of unsatisfactory safety profile in the course of the program. Thus, new approach accelerated access to absolutely indispensable, efficient and safe drugs for about 4 years. Conditional marketing authorization was granted to new drugs used in oncology, ophthalmology, neurology and infectious diseases.

US FDA practices a similar approach – administration grants accelerated approval for drugs used to treat serious and rare diseases since 1992. For accelerated registration, the efficacy of the drug should be proven at least through surrogate endpoints, i.e. any parameter that is a predictor of clinical efficacy but doesn’t represent clinical efficacy measure itself. This type of approval is given under the condition that clinical efficacy is proven later in phase IV trials.

Due to safety and benefits of conditional and accelerated registration for patients, EMA and FDA decided to collaborate on orphan products, harmonizing their efforts on the procedural level.

Sources:

1. http://www.ema.europa.eu/docs/en_GB/document_library/Report/2017/01/WC500219991.pdf

2. http://www.fda.gov/Drugs/ResourcesForYou/HealthProfessionals/ucm313768.htm

3. http://www.medscape.com/viewarticle/405869_4

Share this entry
  • Share on Twitter
  • Share on WhatsApp
  • Share on Pinterest
  • Share on LinkedIn
  • Share on Tumblr
  • Share on Vk
  • Share on Reddit
  • Share by Mail

YOU MAY ALSO BE INTERESTED IN

Publications
Readability User Testing of Package Information Leaflets (PIL) in EAEU
Read More
Publications
Remote clinical trial monitoring
Read More
Publications
Post-authorization studies of drug safety in Russia
Read More

RUBRICS

Registration strategy and Сonsulting

Clinical trials

Registration

Post-authorization clinical studies

Pharmacovigilance

LATEST PUBLICATIONS

  • Corrections to clinical trial documents due to COVID-19. Russian experience.
  • WHAT IS BIOEQUIVALENCE
  • THE VOLUME OF RUSSIAN PHARMACEUTICAL MARKET 2016-2019

Tags

bioequivalenceClinical trials in the CISfeasibilitymonitoringRadiopharmaceuticals

CONTACT

2 + 0 = ?

This contact form is deactivated because you refused to accept Google reCaptcha service which is necessary to validate any messages sent by the form.

PRIVACY

Use of this site constitutes your consent to our Privacy Policy.


SOCIAL RESPONSIBILITY

X7 Research’s primary responsibility is to help our clients in bringing medicines & products to the market efficiently and safely.

The Best CRO for Clinical Trials | Full-service Global CRO — X7 Research

The Best CRO in Pharma | Clinical Research Organisation — X7 Research

The Best Contract Research Organisation (CRO) | Trusted CRO — X7 Research

The Best Clinical Research Organisation (CRO): Full Service CRO | X7 Research

The Best CRO in Research | Trusted CRO for Your Trail — X7 Research

The Best Clinical Trial Company | Global Full-service CRO - X7 Research

The Best Pharma CROs: Clinical Trials for Drugs | X7 Research

The Best CROs Company: Clinical Trials with Global CRO — X7 Research

The Best Pre-clinical CRO: Safety Assessment With X7 Research

The Best Clinical Development | Trusted CRO for Your Product: X7 Research

The Best Biostatistical Consulting: Statistical Services | X7 Research

The Best Pharmacovigilance Consulting Services | CRO — X7 Research

Feasibility in Clinical Trials: What is a Feasibility in Clinical Trials?

Clinical Study Trials: What are Clinical Study Trials?

Category
Strategy and consulting
Clinical trials
Registration
Post-authorization clinical studies
Pharmacovigilance

Registration strategy and Сonsulting
Registration strategy development
Budgeting
Study feasibility
Vendor selection
Data search and analysis

Clinical trials
Development of medical documentation and biostatistics
Monitoring
Data management
Patient home visits
Bioequivalence study
Therapeutic equivalence studies

Registration
Audit of the registration dossier
Dossier eaeu
Conversion of registration dossier into xml format
Pil readability user testing
Turnkey registration

Post-authorization clinical studies
Phase iv studies
Non interventional studies
Investigator initiated studies
Post authorisation safety study
Marketing research

Pharmacovigilance
Building a pharmacovigilance system
Safety in clinical trials
Pharmacovigilance audit
Pharmacovigilance contact person

Blog
Contacts

© Copyright 2010-2023 - X7 Research. All rights reserved.
Advanced Training Course Prospective medical device safety surveillance: role of tracking and databa...
Scroll to top